Right atrial hypertrophy: what it is and how it manifests itself

Right atrial (RA) hypertrophy or enlargement is a structural and functional change in the chamber that occurs due to chronic volume or pressor overload: with tricuspid regurgitation, pulmonary hypertension, chronic lung diseases, congenital defects (e.g., atrial septal defect, Ebstein's anomaly), etc. Clinically, we most often see an increase in RA volume and its remodeling; true concentric "wall hypertrophy" is less common and usually secondary. Not only the geometry, but also the function of the RA as a reservoir/conductor/pump is important, because it is this function that is associated with prognosis. [1]

The RA receives systemic venous blood and pumps it into the right ventricle; therefore, any sustained increase in pulmonary pressure or "backflow" through the tricuspid valve leads to chamber distension. These processes may be reflected on the ECG by tall, "peaked" P waves in the pulmonary arteries, but the specificity and sensitivity of ECG criteria are limited, and the "gold standard" for assessing size/function is echocardiography with indexed volumes, RA area, and right atrial (vena cava) pressure assessment. [2]

The clinical significance of RA enlargement is twofold. On the one hand, it is a marker of the severity of the underlying process (e.g., pulmonary hypertension) and deterioration in hemodynamics; on the other hand, it is an independent predictor of events in certain groups (especially pulmonary hypertension), since RA dysfunction is associated with right-sided decompensation and arrhythmias. Therefore, the physician's task is to identify the cause, assess the degree and function of the RA, and develop cause-based therapy. [3]

In daily practice, it is important to remember that ECG signs of RAE often yield false-positive results; decisions on investigation and treatment should be based on imaging (echo/CT/MRI) and clinical findings, rather than the shape of the P wave in a single lead. In children and young adults, the finding of "RAE on ECG" especially requires confirmation by echocardiography. [4]

Epidemiology

The precise "population" scale of RAE depends on the method. A large study of the general population, normalizing PP size by height, showed that PP exceeding the 95th percentile was associated with increased overall mortality (HR ≈1.7) over a period of ~11 years; PP volume also correlated with body mass index, heart failure, coronary heart disease, and atrial fibrillation. This underscores the role of PP as an integral marker of stress. [5]

According to cardiac MRI and ECG data in adults, the prevalence of true RAE by imaging is ~10-11%, while by ECG criteria, RAE occurred in only ~5%, and the agreement between the methods was moderate. In children and adolescents, the positive predictive value of "RAE on ECG" is low (about 14%), but is higher in infants and in those with simultaneous signs of right ventricular hypertrophy. [6]

In specialized cohorts, the frequency of RAE is higher: in pulmonary arterial hypertension (PAH), RA dilation/dysfunction is common and carries prognostic information; and in severe tricuspid regurgitation, RA enlargement is a typical finding, part of the anatomical phenotype. [7]

In athletes, physiological enlargement of the chambers, including the RA (as part of the "athlete's heart"), is possible with preserved function; here, full echocardiographic criteria and context are critical - including the exclusion of pulmonary hypertension and valvular defects. [8]

Reasons

The main mechanisms are volume overload (e.g., with tricuspid regurgitation, atrial septal defects, Ebstein's anomaly with "atrialization" of the RV inlet tract) and pressor overload (chronic increase in pressure in the pulmonary artery/right ventricle). Both scenarios lead to dilation of the RA and remodeling of its wall and the interatrial septum. [9]

Pulmonary hypertension (idiopathic, associated with lung diseases, left heart disease, etc.) is a common cause for an increase in RA; in such cases, an increase in RA volume/area reflects chronic pressure overload and deterioration of the function of the right ventricles. [10]

Congenital defects (Ebstein's anomaly, primary interatrial septal defect, tetralogy of Fallot, pulmonary artery stenosis) directly alter the geometry of the right chambers and predispose to RA dilation and arrhythmias. In Ebstein's anomaly, for example, apical displacement of the tricuspid valve leaflets and "atrialization" of part of the right ventricle increase the load on the RA. [11]

Finally, chronic lung diseases (corpus pulmonale), obstructive sleep apnea syndrome, post-thromboembolic hypertension, and long-term atrial tachyarrhythmia (flutter/fibrillation) lead to an increase in PP, when “arrhythmogenic” remodeling and volume load support each other. [12]

Risk factors

Risk factors for RAE include all conditions that increase pulmonary arterial pressure (pulmonary hypertension, COPD, interstitial lung diseases), as well as volume load on the right heart (moderate/severe tricuspid regurgitation, congenital shunts). The risk increases with prolonged disease progression and inadequate control of the underlying disease. [13]

Metabolic/cardiovascular factors (obesity, CVD, diabetes) are associated with large RA volumes even in the general population. This highlights the role of modifiable factors in long-term atrial remodeling. [14]

In athletes, high atrial volumes are possible as a physiological adaptation, but the upper reference limits should be taken into account, and controversial cases should be assessed multiparametrically (pressure in the RA along the inferior vena cava, RA function, pressure in the pulmonary artery). [15]

In children/young people, congenital causes are common; in the elderly, it is often a combination of PAH due to left-sided heart disease (ESC/ERS group 2) and secondary tricuspid regurgitation due to right-sided heart dilation. [16]

Pathogenesis

Prolonged volume or pressor overload activates mechanotransduction and causes eccentric dilation of the RA, changes in the extracellular matrix, and decreased compliance. The RA loses its "reservoir" and "pumping" functions, which impairs filling and systolic ejection of the RV. [17]

At the pulmonary circulation level, pulmonary hypertension leads to increased RV afterload, its dilation/dysfunction, and further to a retrograde increase in RA pressure. The degree of RA enlargement and the increase in pressure in it correlate with outcomes in PAH. [18]

In tricuspid regurgitation, volume overload occurs directly in the RA; modern scales of TR severity (up to “massive/torrential”) emphasize that extreme TR dramatically alters the geometry of the RA and is associated with an unfavorable prognosis if the regurgitation is not eliminated. [19]

In Ebstein's anomaly, atrialization of the RV inlet mechanically increases the volume of the atrial cavity and predisposes to tachyarrhythmias; giant/wide P waves and signs of right-sided overload serve as markers. [20]

Symptoms

Symptoms are determined by the underlying cause. In pulmonary hypertension and right ventricular failure, symptoms include shortness of breath during exertion, fatigue, jugular vein distension, peripheral edema, and ascites. Many patients complain of a feeling of heaviness in the right hypochondrium due to venous congestion. [21]

In severe tricuspid regurgitation, there is a pulsating sensation in the neck/right hypochondrium, severe swelling, and exercise intolerance. In congenital defects, there is shortness of breath, cyanosis (with shunts/cyanotic defects), and delayed physical development in children. [22]

Atrial arrhythmias (flutter, fibrillation) are common in the setting of RAE and themselves exacerbate remodeling. Patients report palpitations, irregular heartbeats, and decreased exercise tolerance; strokes and TIAs are possible with AF. [23]

Separately, asymptomatic enlargement of the RA, detected incidentally by ECG/echo, is possible. Even in this case, it is significant as a risk marker and a reason to seek a cause, especially if the RA volume/area is outside the normal range. [24]

Forms and stages

Clinically and etiologically, the following are distinguished: (1) RAE with volume overload (tricuspid regurgitation, shunts), (2) with pressor overload (PAH of all groups), (3) with congenital defects (Ebstein's anomaly, etc.), (4) athletic adaptation (a normal variant with appropriate criteria). [25]

The degree of enlargement is determined by the RA area and RA volume index (RA area, RA volume index), as well as by the pressure in the RA (according to the IVC). For simplicity, a number of documents use the RA area threshold >18 cm² as an indicator of enlargement (individual interpretation based on body type is mandatory). [26]

Functionally, the reservoir/conduit/pump functions are assessed (including by deformation/strain of the RA); in PAH, a decrease in RA function and an increase in RA pressure are associated with worse outcomes. [27]

“Staging” is determined by the underlying disease: for example, in the case of PAH – risk stages according to ESC/ERS; in TR – gradation up to “torrential”; in the case of congenital pathology – anatomical classes and consequences. [28]

Complications and consequences

RAE increases the risk of supraventricular arrhythmias (flutter/AF), thromboembolism in AF, and right ventricular decompensation in PAH/TR. In PAH cohorts, RA dysfunction independently predicts hospitalization and mortality. [29]

In severe TR and pronounced RAE, the incidence of liver congestion and cachexia increases, and exercise tolerance decreases. If the underlying cause is not addressed promptly, it leads to a progressive deterioration in quality of life. [30]

In congenital defects (e.g., Ebstein's), tachyarrhythmias are common (including AV reentry with accessory pathways), and episodes of cyanosis and heart failure are possible. Timely correction reduces the volume of the RA and the risk of arrhythmias. [31]

In the general population, PP volume outside the reference range is associated with increased mortality - therefore, even an “asymptomatic” finding requires explanation and dynamic monitoring. [32]

Diagnostics

ECG: Tall, peaked P waves in II/III/aVF (>2.5 mm) and/or V1-V2 (>1.5 mm) are traditionally interpreted as signs of RAE (P pulmonale). However, sensitivity is low and specificity varies by gender/criteria; ECG should not be the sole basis for diagnosis. [33]

Echocardiography is the method of choice: the RA area is measured (normal ≲18 cm² as a general threshold) and the RA volume index (guidelines of about ~21 ml/m² in women and ~25 ml/m² in men as upper reference values according to research data; interpretation according to BSA/height is mandatory), the RA pressure is assessed by the size/collapse of the inferior vena cava, the TR velocity and probable pulmonary artery pressure, as well as the structure/function of the tricuspid valve. [34]

Cardiac MRI/CT is used when visualization is insufficient, anatomy is complex (congenital defects), or for precise RA volume determination. Right-sided catheterization is the standard for confirmation and phenotyping of pulmonary hypertension; echocardiography is used for screening/stratification, but the diagnosis of PAH is established invasively. [35]

Laboratory tests are used to look for causes: natriuretic peptides in right ventricular failure, TSH (in thyrotoxicosis - a trigger for arrhythmia), tests for lung diseases/immune causes of PAH; in case of arrhythmias - assessment of the risk of stroke. [36]

Table 1. ECG criteria of RAE and their diagnostic value

Criterion	Threshold	Comments
P pulmonale in II/III/aVF	amplitude P >2.5 mm	Classic sign, but sensitivity is low. [37]
P in V1-V2	>1.5 mm	May increase sensitivity in men.[38]
Combined criteria (P II ≥2 mm + P V1 ≥1 mm)	-	Higher specificity in women; overall sensitivity is limited. [39]
General conclusion	-	ECG signs require confirmation by echocardiography. [40]

Table 2. Echo threshold values for PP (guidelines)

Parameter	Norm (guideline)	Increase
RA area	≤18 cm²	>18 cm² (taking into account gender/height) [41]
PP volume index (RA Vi)	~≤21 ml/m² (f), ≤25 ml/m² (m)	Above reference (indexed by BSA/height) [42]
Pressure in the right ventricle (according to the lower extremity pressure)	IVC ≤2.1 cm and collapse >50%	Signs of high blood pressure in the right pelvis [43]
TRV speed	<2.8-2.9 m/s	At ≥2.8-2.9 m/s, pulmonary hypertension is possible (in context) [44]

Differential diagnosis

Athletic heart vs. pathological RAE: in trained individuals, symmetrical chamber enlargement with preserved function and no signs of PAH/significant TR. If in doubt, multiparametric evaluation, sometimes MRI. [45]

Group 2 PAH (due to left compartments) vs. primary PAH: key features are clinical features, echo profile of left chambers/valves; diagnosis of PAH requires catheterization with measurement of wedge pressure. [46]

Congenital defects (Ebstein's anomaly, ASD) vs. isolated secondary TR: signs of valve anatomy (apical displacement of the leaflets in Ebstein's anomaly >8 mm/m²), the presence of shunts/delta waves, etc. are helpful [47]

Acute overload (pulmonary embolism) vs. chronic remodeling: CT angiography, D-dimer clinical findings, echo signs of acute RV overload (paradoxical septum, acute increase in pressure in the RA). [48]

Table 3. "Pathological RAE or normal variants?"

Situation	For pathology	For physiology
Athlete	Increased pressure in the right ventricle/left ventricle, TR ≥ moderate	Normal RA/RV function, absence of LH [49]
Suspected PAH	TRV ≥2.8-2.9 m/s + additional signs	TRV is low, no other markers [50]
Ebstein vs. secondary TR	Apical displacement of the valves >8 mm/m²	No displacement; secondary changes [51]
ECG-RAE	Large P waves in the inferior leads	False positive, echo verification required [52]

Treatment

The basic principle: treat the underlying cause of RAE (PAH, TR, congenital defect, lung disease, arrhythmia). "Large PP" itself isn't a target for medications, but it directs us toward an active strategy for the underlying disease.

Pulmonary hypertension (PAH/pulmonary arterial, ESC/ERS groups). 2022 algorithm: catheterization confirmation, multiparametric risk assessment and early combination therapy in eligible patients (ET-receptor inhibitors, PDE5 inhibitors/guanylate cyclase stimulators, prostacyclin pathway inhibitors), risk escalation; dynamic reassessment. PP monitoring (volume/pressure/function) is part of therapy response monitoring. [53]

Tricuspid regurgitation (secondary/functional and primary). Medication: treat the underlying cause (control of pulmonary/left ventricular hemodynamics, diuretics for congestion). In moderate-severe/severe TR with symptoms and RA/RV dilation, consider interventional correction: surgical repair/prosthetics or transcatheter methods (edge-to-edge repair, annuloplasty, orthotopic replacement), which are actively developing in 2024-2025 and improve the prognosis in properly selected patients. [54]

Congenital defects. In Ebstein's anomaly, individualized tricuspid valve surgery/reduction of the atrialized portion of the right ventricle is recommended; in ASD, transcatheter/surgical closure is recommended in cases of significant shunting and right ventricular overload. Correction of the primary anatomy often reduces the volume of the right atrium and the risk of arrhythmia. [55]

Atrial arrhythmias. Rate/rhythm control according to standards, anticoagulation according to stroke risk scales. For typical atrial flutter – ablation of the cavo-tricuspid isthmus (>95% success); for AF – the strategy depends on symptoms/structure; reducing the volume and pressure in the RA by treating the cause reduces the "arrhythmogenic soil". [56]

Lung diseases / COPD / OSA. Basic therapy for COPD, oxygen for hypoxemia, and apnea treatment (CPAP) are critical for reducing right ventricular afterload and stabilizing the right atrium. In post-thromboembolic pulmonary hypertension, consider endarterectomy/balloon angioplasty. [57]

Table 4. Therapeutic “branches” for RAE

Cause	The path of treatment	What we strive for
LAG	Combination specific therapy ± escalation	Reduction of risk, pressure in the right atrium/heart attack, improvement of the right atrium/heart attack function [58]
Tricuspid regurgitation	Diuretics, correction of the underlying condition; surgery/TCI if indicated	Reduction of regurgitation and overload of the right atrium [59]
Congenital defects	Surgical/endovascular correction of anatomy	Normalization of hemodynamics, ↓volume of PP [60]
Atrial arrhythmias	Heart rate/rhythm monitoring, ablation, risk-based OAC	↓symptoms/strokes, stabilization of remodeling
Lung diseases/OSA	COPD/CPAP therapy/revascularization for CTEPH	↓ afterload of the right ventricle, stabilization of the right atrium [61]

Table 5. When to refer to a specialist/center

Situation	To whom	For what
Suspected PAH	LG Center	Catheterization, phenotype, start of targeted therapy. [62]
Moderate-severe/severe TR	Cardiac surgeon/interventional cardiologist	Assessment for plastic surgery/TK-correction. [63]
Congenital pathology	VPS Center	Complete morphological assessment and correction. [64]
Unclear RAE in an athlete	Sports cardio/echo expert	Differentiate between adaptation and pathology. [65]

Prevention

There is no specific "prevention" for RA enlargement; prevention is aimed at the underlying causes: adequate control of blood pressure, weight, and sleep apnea, smoking cessation, and timely treatment of lung diseases reduce the risk of pulmonary hypertension and secondary regurgitation. Early detection of valvular defects and their correction before the development of significant RA dilation improves long-term hemodynamics. [66]

For patients with established PAH, TR, or CHD, regular visits and echocardiography, adherence to medications, and rehabilitation (aerobic exercise within a safe range) are important. For arrhythmias, anticoagulation as indicated and timely ablation (for typical flutter/part of AF) are recommended, which reduces complications and remodeling. [67]

Forecast

The prognosis is determined by the cause and stage. In PAH, RA volume/pressure and function are part of the prognostic mosaic: deterioration of RA function and increased RA pressure are associated with an increased risk of hospitalization and mortality; timely targeted therapy improves these indicators. In severe uncorrected TR, the prognosis is unfavorable, but modern surgical and transcatheter techniques significantly change the trajectory. [68]

In the general population, RA volume exceeding the 95th percentile is associated with increased mortality; however, with adequate treatment of the underlying cause (e.g., shunt closure, TR correction, PAH control), RA volume can partially regress, arrhythmia incidence decreases, and quality of life improves. This explains why RAE should be considered a reversible marker of burden rather than a death sentence. [69]

FAQ

• Does RAE stand for "wall thickening" or "chamber distension"?

Most often, dilation/volume increase is due to volume or pressor overload; "pure" hypertrophy of the RA wall is rare and usually secondary. Echo evaluates the area/volume and pressure in the RA. [70]

• Is it possible to diagnose RAE based on ECG alone (P pulmonale)?

ECG findings are helpful in diagnosing but do not confirm the diagnosis: sensitivity is low, and false positives are common. Echocardiography and a search for the cause are needed. [71]

• What is "normal" for PCB sizes?

A threshold of PP area ≤18 cm² is often used as a normal reference; for volume, indexed references are used (~up to 21 ml/m² in women and 25 ml/m² in men), but it is better to evaluate in combination with body type, PP pressure, and PP function. [72]

• Is "increased PP" treatable on its own?

The underlying cause is treated: PAH - according to the ESC/ERS algorithms; TR - correction up to transcatheter/surgical procedures; congenital defects - anatomical correction; arrhythmias - rhythm/heart rate control and anticoagulation according to risk. Against this background, the volume of RA is often reduced. [73]

• Is RAE life-threatening?

The size itself is not significant, but it does reflect the severity of the underlying process and is associated with the risk of arrhythmias/right ventricular decompensation, especially in PAH and severe TR. With timely targeted therapy, the risk is reduced. [74]

Table 6. Red flags for RAE and steps to take

Flag	Probable cause	Action
Dyspnea, signs of right ventricular failure, TRV ≥2.9 m/s	LG	Referral to the PH center, catheterization. [75]
Moderate-severe/severe TR, progressive edema	Secondary TR	Evaluation for reconstruction/TC intervention. [76]
Abnormal tricuspid valve anatomy	Ebstein's anomaly	Council of Congenital Heart Diseases/Cardiac Surgery. [77]
New AF/flutter + enlarged RA	Atrial arrhythmias	Anticoagulation/ablation as indicated.

Table 7. Key measurements of the echo PP and how they “work” together

What are we measuring?	What does it reflect?	How does it influence the decision?
Area/volume of the PP	Chronic volume/pressure overload	Marker of the severity of the process, dynamics during therapy. [78]
Pressure in the right ventricle (LPV)	Venous congestion/right pressure	Diuretic titration, risk stratification in PAH. [79]
TRV / calculated pressure in the aircraft	Probability of LG	Decision on catheterization/specific therapy. [80]
PP function (strain)	Tank/pump	Prognosis, especially in PAH. [81]